Literature DB >> 30058903

Ovarian function, fertility and reproductive lifespan in cancer patients.

Yasmin L Jayasinghe1, W Hamish B Wallace2, Richard A Anderson3.   

Abstract

INTRODUCTION: The increasing survival of girls and young women after cancer has led to a rapid growth in research into assessment of ovarian function after treatment. AREAS COVERED: This aim of this review is to discuss normal ovarian function over time, the impact of cancer treatment on ovarian function, the assessment of ovarian reserve after treatment, and pretreatment predictors of ovarian recovery. EXPERT COMMENTARY: Ovarian function damage after chemotherapy and radiotherapy will impact on fertility and reproductive lifespan, but with great variability. Age at menopause has implications for the duration of estrogen deficiency, with its own adverse health consequences. This has led to identification of the key treatment and patient factors at the time of treatment, notably age and ovarian reserve that impact on post-treatment ovarian function. However, most studies have used outcome measures such as ongoing menses, or biomarkers such as anti-mullerian hormone (AMH), with few reporting on fertility or age at menopause.

Entities:  

Keywords:  Anti-Mullerian hormone; chemotherapy; ovarian reserve; premature ovarian insufficiency; radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 30058903     DOI: 10.1080/17446651.2018.1455498

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  13 in total

1.  The protective effect of platelet-rich plasma administrated on ovarian function in female rats with Cy-induced ovarian damage.

Authors:  Pinar Ozcan; Taha Takmaz; Olgu Enis Tok; Sevde Islek; Esra Nur Yigit; Cem Ficicioglu
Journal:  J Assist Reprod Genet       Date:  2020-02-04       Impact factor: 3.412

Review 2.  Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up.

Authors:  Hanneke M van Santen; Marry M van den Heuvel-Eibrink; Marianne D van de Wetering; W Hamish Wallace
Journal:  Horm Res Paediatr       Date:  2019-01-31       Impact factor: 2.852

3.  Development of sheep secondary follicles and preservation of aromatase and metalloproteinases 2 and 9 after vitrification and in vitro culture.

Authors:  Francisco Denilson Rodrigues Gomes; Danielle Cristina Calado de Brito; Naíza Arcângela Ribeiro de Sá; Lucy Vanessa Sulca Ñaupas; Gaby Judith Quispe Palomino; Renato Felix da Silva; Éverton Pimentel Ferreira Lopes; Gildas Tetaping Mbemya; Benner Geraldo Alves; Mary Zelinski; José Ricardo de Figueiredo; Ana Paula Ribeiro Rodrigues
Journal:  Cell Tissue Bank       Date:  2021-06-21       Impact factor: 1.522

4.  The Use of AMH to Assess Ovarian Toxicity in Adolescents and Young Adults After Cancer Treatment.

Authors:  Richard A Anderson; W Hamish B Wallace
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

5.  Kinase-independent inhibition of cyclophosphamide-induced pathways protects the ovarian reserve and prolongs fertility.

Authors:  Giovanna Bellusci; Luca Mattiello; Valentina Iannizzotto; Sarah Ciccone; Emiliano Maiani; Valentina Villani; Marc Diederich; Stefania Gonfloni
Journal:  Cell Death Dis       Date:  2019-09-27       Impact factor: 8.469

Review 6.  Ovarian damage from chemotherapy and current approaches to its protection.

Authors:  N Spears; F Lopes; A Stefansdottir; V Rossi; M De Felici; R A Anderson; F G Klinger
Journal:  Hum Reprod Update       Date:  2019-11-05       Impact factor: 15.610

7.  Efficacy of assisted reproductive technology after ovarian tissue transplantation in a cohort of 11 patients with or without associated infertility factors.

Authors:  M Vatel; A Torre; B Paillusson; F Scheffler; M Bergere; M Benkhalifa; M-T Le Martelot; F Leperlier; S Mirallié; L Selleret; M Prades-Borio; A Neuraz; V Barraud-Lange; N Boissel; A Fortin; C Poirot
Journal:  J Assist Reprod Genet       Date:  2021-01-03       Impact factor: 3.412

Review 8.  The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery.

Authors:  Queenie Ho Yan Wong; Richard A Anderson
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-12       Impact factor: 3.243

9.  Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.

Authors:  Richard A Anderson; Rachel Remedios; Amy A Kirkwood; Pip Patrick; Linsey Stevens; Laura Clifton-Hadley; Tom Roberts; Chris Hatton; Nagesh Kalakonda; Don W Milligan; Pam McKay; Clare Rowntree; Fiona M Scott; Peter W M Johnson
Journal:  Lancet Oncol       Date:  2018-09-13       Impact factor: 54.433

10.  Exploring the facilitators and barriers to using an online infertility risk prediction tool (FoRECAsT) for young women with breast cancer: a qualitative study protocol.

Authors:  Zobaida Edib; Yasmin Jayasinghe; Martha Hickey; Lesley Stafford; Richard A Anderson; H Irene Su; Kate Stern; Christobel Saunders; Antoinette Anazodo; Mary Macheras-Magias; Shanton Chang; Patrick Pang; Franca Agresta; Laura Chin-Lenn; Wanyuan Cui; Sarah Pratt; Alex Gorelik; Michelle Peate
Journal:  BMJ Open       Date:  2020-02-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.